<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541537</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2020 08</org_study_id>
    <nct_id>NCT04541537</nct_id>
  </id_info>
  <brief_title>Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer.</brief_title>
  <acronym>KDOGCOV</acronym>
  <official_title>Feasibility Study on the Possibility of Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To ascertain the possibilities to isolate the breast cancer olfactive signature&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient recruitment during the first surgery consultation in Curie Institute.&#xD;
&#xD;
      Odor sampling (non-invasive) with an odor-sensing polymer (Sorbstar® polymer developed&#xD;
      especially for the trace level analysis), on:&#xD;
&#xD;
        -  The hands, before and after surgical excision of the tumor (friction of the hands)&#xD;
&#xD;
        -  The diseased breast, before and after surgical excision of the tumor (via a compress&#xD;
           positioned on the breast for 1 night)&#xD;
&#xD;
        -  The tumor, during the surgical procedure (odor collection over a tumor sample).&#xD;
&#xD;
      Each patient will be her own witness, before and after surgical excision, in an attempt to&#xD;
      isolate the chemical signature tracks of breast cancer. The samples after surgery will be&#xD;
      made after healing and before implementation of a treatment (chemotherapy and / or&#xD;
      radiotherapy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Experimental, interventional, prospective, open, monocentric study with risks and minimal constraints</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To ascertain the possibilities to isolate the breast cancer olfactive signature</measure>
    <time_frame>18 months</time_frame>
    <description>Isolation of volatile Organic Compounds to breast cancer by a sensitive technique with an odor-sensing polymer (Sorbstar®) on hands. Friction of the hands according to the protocol before and after surgical excision of the tumor. Sorbstar® analyses will be performed with a thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ascertain breast cancer olfactive signature from the tumor (Isolation of volatile Organic Compounds to tumor breast samples by a sensitive technique with an odor-sensing polymer (Sorbstar®)</measure>
    <time_frame>18 months</time_frame>
    <description>During the surgical procedure an odor-sensing polymer (Sorbstar®) over the tumor is placed. Sorbstar® analyzes will be performed with a thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascertain breast cancer detection by the dogs of Curie Institut</measure>
    <time_frame>18 months</time_frame>
    <description>Patients sleep over a night with a compress positioned on the affected breast before and after surgery. The compress will be analyzed by the dogs of Curie Institut (results cancer/not cancer).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Sorbstar®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Odour sampling : rub hands with Sorbstars® before and post-surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dog Detection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Odour sampling :sleep over a night with a compress on the affected breast before and after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sorbstar®</intervention_name>
    <description>Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry</description>
    <arm_group_label>Sorbstar®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dog Detection</intervention_name>
    <description>Analysed by the dogs of Curie Institute at the training centers</description>
    <arm_group_label>Dog Detection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient received in surgery consultation for an invasive non metastatic breast cancer&#xD;
             treated by breast-conserving surgery with axillary or sentinel node dissection&#xD;
&#xD;
          2. Of-Age female patient (over 18 years old)&#xD;
&#xD;
          3. Life expectancy &gt; to 1 year at the inclusion&#xD;
&#xD;
          4. ECOG performance status: 0 or 1 or 2&#xD;
&#xD;
          5. Patient benefiting from the social security&#xD;
&#xD;
          6. Signature informed consent of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neoplasia in progress or neoplasia history of cancer other than breast to be treated.&#xD;
&#xD;
          2. Wound presence on breasts&#xD;
&#xD;
          3. Male subjects&#xD;
&#xD;
          4. Pregnant or lactating women&#xD;
&#xD;
          5. Specified metastatic breast cancer&#xD;
&#xD;
          6. Concomitant medication taken one month before the surgical act (antibiotics,&#xD;
             corticoids, anti-diabetics)&#xD;
&#xD;
          7. Persons under guardianship or deprived of liberty&#xD;
&#xD;
          8. Impossibility to submit to the medical monitoring expected by the study for&#xD;
             geographical, social or psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fromantin Isabelle, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fromantin Isabelle, PhD</last_name>
    <phone>+33144324428</phone>
    <email>isabelle.fromantin@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle FROMANTIN, PHD</last_name>
      <email>isabelle.fromantin@curie.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

